Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered With Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2023
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Hypertriglyceridaemia
- Focus Biomarker; Therapeutic Use
- Sponsors GSK; Reliant Pharmaceuticals
- 01 Feb 2010 Results published in the Mayo Clinic Proceedings.
- 08 Nov 2008 Results presented at the 81st Annual Scientific Sessions of the American Heart Association.
- 06 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.